190 related articles for article (PubMed ID: 37072666)
21. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs.
Nakazato I; Shiomi T; Oyama K; Matsuno A; Inomoto C; Yoshiyuki Osamura R
Acta Histochem Cytochem; 2023 Dec; 56(6):121-126. PubMed ID: 38318106
[TBL] [Abstract][Full Text] [Related]
23. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
[TBL] [Abstract][Full Text] [Related]
24. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.
Asa SL
Endocr Pathol; 2021 Jun; 32(2):222-227. PubMed ID: 33866514
[TBL] [Abstract][Full Text] [Related]
25. PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion.
Tamura R; Ohara K; Morimoto Y; Kosugi K; Oishi Y; Sato M; Yoshida K; Toda M
Endocr Pathol; 2019 Jun; 30(2):81-89. PubMed ID: 30903445
[TBL] [Abstract][Full Text] [Related]
26. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
[TBL] [Abstract][Full Text] [Related]
27. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
Rak B; Maksymowicz M; Pękul M; Zieliński G
Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
[TBL] [Abstract][Full Text] [Related]
28. [Epidemiology, Genetics and Pathogenesis of Pituitary Neuroendocrine Tumors].
Suzuki K; Tahara S
No Shinkei Geka; 2023 Jul; 51(4):593-606. PubMed ID: 37491056
[TBL] [Abstract][Full Text] [Related]
29. [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].
Kurosaki M
No Shinkei Geka; 2023 Sep; 51(5):910-916. PubMed ID: 37743343
[TBL] [Abstract][Full Text] [Related]
30. [WHO Histological Classification of Pituitary Tumors].
Nishioka H
No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
[TBL] [Abstract][Full Text] [Related]
31. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
32. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.
Mete O; Wenig BM
Head Neck Pathol; 2022 Mar; 16(1):123-142. PubMed ID: 35312985
[TBL] [Abstract][Full Text] [Related]
33. Multiple tumorous lesions of the pituitary gland.
Schöning JV; Flitsch J; Lüdecke DK; Fahlbusch R; Buchfelder M; Buslei R; Knappe UJ; Bergmann M; Schulz-Schaeffer WJ; Herms J; Glatzel M; Saeger W
Hormones (Athens); 2022 Dec; 21(4):653-663. PubMed ID: 35947342
[TBL] [Abstract][Full Text] [Related]
34. "Honeycomb Golgi" in pituitary adenomas: not a marker of gonadotroph adenomas.
Sano T; Mader R; Asa SL; Qian ZR; Hino A; Yamada S
Endocr Pathol; 2003; 14(4):363-8. PubMed ID: 14739492
[TBL] [Abstract][Full Text] [Related]
35. Neuropathology of Pituitary Adenomas and Sellar Lesions.
Kobalka PJ; Huntoon K; Becker AP
Neurosurgery; 2021 Apr; 88(5):900-918. PubMed ID: 33476394
[TBL] [Abstract][Full Text] [Related]
36. Estrogen Receptors in Nonfunctioning Pituitary Neuroendocrine Tumors: Review on Expression and Gonadotroph Functions.
Haydar Ali Tajuddin A; Kamaruddin N; Sukor N; Azizan EA; Omar AM
J Endocr Soc; 2020 Dec; 4(12):bvaa157. PubMed ID: 33241169
[TBL] [Abstract][Full Text] [Related]
37. A review of multiomics platforms in pituitary adenoma pathogenesis.
Mouchtouris N; Smit RD; Piper K; Prashant G; Evans JJ; Karsy M
Front Biosci (Landmark Ed); 2022 Mar; 27(3):77. PubMed ID: 35345309
[TBL] [Abstract][Full Text] [Related]
38. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
[TBL] [Abstract][Full Text] [Related]
39. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
[TBL] [Abstract][Full Text] [Related]
40. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
